ALSO NOTED: Illumina ordered to pay for patent violations; Cytyc to restate financials;and much more...

> A federal court has ruled that Illumina must pay Affymetrix $16.7 million for violating five patents involving genetic variation analysis. Report

> Cytyc will restate 10 years of financial statements. Report

> Neose Technologies has been cleared by the FDA to commence clinical trials for NE-180 in the United States. Release

> Napo Pharmaceuticals has received approval from the principal independent review board overseeing the Phase III study of crofelemer for diarrhea in people living with HIV/AIDS. Release

> Cambridge, MA-based Curis has selected the first development candidate from its Targeted Cancer Drug Development Platform. Release

And Finally… Don't schedule your heart attack for a weekend. A new study shows that mortality rates on heart attacks climbs from a weekday average of 12 percent to 12.9 percent on the weekend. Article

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.